Phototherapy in ELBW newborns: Does it work? Is it safe? The evidence from randomized clinical trials

Seminars in Perinatology

Volumn 38, Issue 7, 2014, Pages 452-464

  Arnold, Cody ^a   Pedroza, Claudia ^a   Tyson, Jon E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bilirubin; Extremely low birthweight; Neurodevelopmental outcome; Phototherapy; Safety

Indexed keywords

BILIRUBIN; HEME OXYGENASE INHIBITOR; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN ZINC; STANNSOPORFIN; UNCLASSIFIED DRUG; ZINC BISGLYCOL;

ARTIFICIAL VENTILATION; BILIRUBIN BLOOD LEVEL; BRAIN INJURY; DEVELOPMENTAL DISORDER; DRUG EFFICACY; EXCHANGE BLOOD TRANSFUSION; EXTREMELY LOW BIRTH WEIGHT; FIBER OPTICS; FLUORESCENT LIGHTING; HUMAN; HYPERBILIRUBINEMIA; INTERMETHOD COMPARISON; LIGHT EMITTING DIODE; LIGHT IRRADIANCE; MECHANICAL VENTILATOR; NEWBORN DEATH; NEWBORN JAUNDICE; NEWBORN MORTALITY; NONHUMAN; PATIENT SAFETY; PHOTOTHERAPY; PHOTOTHERAPY DEVICE; PHOTOTOXICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; THERAPY EFFECT; TREATMENT OUTCOME; ADVERSE EFFECTS; BAYES THEOREM; BIRTH WEIGHT; BLOOD; DEVELOPMENTAL DISABILITIES; FOLLOW UP; GESTATIONAL AGE; GROWTH, DEVELOPMENT AND AGING; HYPERBILIRUBINEMIA, NEONATAL; INFANT; INFANT MORTALITY; INFANT, PREMATURE, DISEASES; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NEWBORN; PREMATURITY; PROCEDURES; RISK ASSESSMENT;

BAYES THEOREM; BILIRUBIN; BIRTH WEIGHT; DEVELOPMENTAL DISABILITIES; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; HYPERBILIRUBINEMIA, NEONATAL; INFANT; INFANT MORTALITY; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; PHOTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84908129441     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2014.08.008     Document Type: Review

References (83)

1. Maisels M.J. Phototherapy-traditional and nontraditional. J Perinatol 2001, 21(suppl 1):S93-S97. [discussion S104-107].
2. Ritter D.A., Kenny J.D., Norton H.J., Rudolph A.J. A prospective study of free bilirubin and other risk factors in the development of kernicterus in premature infants. Pediatrics 1982, 69(3):260-266.
3. Lucey J.F. Bilirubin and brain damage-a real mess. Pediatrics 1982, 69(3):381-382.
4. Cashore W.J. Bilirubin and jaundice in the micropremie. Clin Perinatol 2000, 27(1):171-179.
5. Shapiro S.M. Bilirubin toxicity in the developing nervous system. Pediatr Neurol 2003, 29(5):410-421.
6. Shapiro S.M. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol 2005, 25(1):54-59.
7. Mazeiras G., Rozé J.-C., Ancel P.-Y., et al. Hyperbilirubinemia and neurodevelopmental outcome of very low birthweight infants: results from the LIFT cohort. PLoS One 2012, 7(1):e30900.
8. Harris R.C., Lucey J.F., MacLean J.R. Kernicterus in premature infants associated with low concentrations of bilirubin in the plasma. Pediatrics 1958, 21(6):875-884.
9. Watchko J.F., Jeffrey Maisels M. Enduring controversies in the management of hyperbilirubinemia in preterm neonates. Semin Fetal Neonatal Med 2010, 15(3):136-140.
10. Ahlfors C.E. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr 2001, 139(2):317-319.
11. Jardine D.S., Rogers K. Relationship of benzyl alcohol to kernicterus, intraventricular hemorrhage, and mortality in preterm infants. Pediatrics 1989, 83(2):153-160.
12. Odell G.B., Schaffer R., Simopoulos A.P. Phototherapy in the Newborn: An Overview 1974, National Academy of Sciences, Washington, DC.
13. Behrman R.E., Brown A.K., Currie M.R., et al. Preliminary report of the committee on phototherapy in the newborn infant. J Pediatr 1974, 84(1):135-143.
14. Hintz S.R., Stevenson D.K., Yao Q., et al. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants?. Acta Paediatr 2011, 100(7):960-965.
15. Tyson J.E., Pedroza C., Langer J., et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns?. J Perinatol 2012, 32(9):677-684.
16. Van de Bor M., van Zeben-van der Aa T.M., Verloove-Vanhorick S.P., Brand R., Ruys J.H. Hyperbilirubinemia in preterm infants and neurodevelopmental outcome at 2 years of age: results of a national collaborative survey. Pediatrics 1989, 83(6):915-920.
17. Van de Bor M., Ens-Dokkum M., Schreuder A.M., Veen S., Brand R., Verloove-Vanhorick S.P. Hyperbilirubinemia in low birth weight infants and outcome at 5 years of age. Pediatrics 1992, 89(3):359-364.
18. Oh W., Tyson J.E., Fanaroff A.A., et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics 2003, 112(4):773-779.
19. Vreman H.J., Wong R.J., Stevenson D.K. Phototherapy: current methods and future directions. Semin Perinatol 2004, 28(5):326-333.
20. Watchko J.F., Tiribelli C. Bilirubin-induced neurologic damage-mechanisms and management approaches. N Engl J Med 2013, 369(21):2021-2030.
21. Ruud Hansen T.W. Phototherapy for neonatal jaundice-therapeutic effects on more than one level?. Semin Perinatol 2010, 34(3):231-234.
22. Maisels M., Watchko J. Treatment of jaundice in low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2003, 88(6):F459-F463.
23. Watchko J., Maisels M. Jaundice in low birthweight infants: pathobiology and outcome. Arch Dis Child Fetal Neonatal Ed 2003, 88(6):F455-F458.
24. McDonagh A.F. Phototherapy: from ancient Egypt to the new millennium. J Perinatol 2001, 21(suppl 1):S7-S12.
25. Fletcher R.H. Clinical Epidemiology: The Essentials 2005, Lippincott Williams & Wilkins, Philadelphia, PA. 4th ed.
26. Bryla D.A. Development, design, and sample composition. Pediatrics 1985, 75(2):387-441.
27. Brown A.K., Kim M.H., Wu P.Y., Bryla D.A. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985, 75(2 Pt 2):393-400.
28. Lipsitz P.J., Gartner L.M., Bryla D.A. Neonatal and infant mortality in relation to phototherapy. Pediatrics 1985, 75(2 Pt 2):422-426.
29. Scheidt P.C., Bryla D.A., Nelson K.B., Hirtz D.G., Hoffman H.J. Phototherapy for neonatal hyperbilirubinemia: six-year follow-up of the National Institute of Child Health and Human Development clinical trial. Pediatrics 1990, 85(4):455-463.
30. Hack M., Taylor H.G., Drotar D., et al. Poor predictive validity of the Bayley Scales of Infant Development for cognitive function of extremely low birth weight children at school age. Pediatrics 2005, 116(2):333-341.
31. Roberts G., Anderson P.J., Doyle L.W. The stability of the diagnosis of developmental disability between ages 2 and 8 in a geographic cohort of very preterm children born in 1997. Arch Dis Child 2010, 95(10):786-790. Victorian Infant Collaborative Study Group.
32. National Institute of Child Health and Human Development Randomized controlled trial of phototherapy for neonatal hyperbilirubinemia - Executive Summary. Pediatrics 1985, 75(2):385-386.
33. Scheidt P.C., Graubard B.I., Nelson K.B., et al. Intelligence at six years in relation to neonatal bilirubin levels: follow-up of the National Institute of Child Health and Human Development Clinical Trial of Phototherapy. Pediatrics 1991, 87(6):797-805.
34. Gopinathan V., Miller N.J., Milner A.D., Rice-Evans C.A. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett 1994, 349(2):197-200.
35. Morris B.H., Oh W., Tyson J.E., et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med 2008, 359(18):1885-1896.
36. Newman TB, Grady DG, Browner WS, Cummings SR, Hulley SB. Designing cross-sectional and case-control studies (Chapter 8). In: Designing Clinical Research. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007 ISBN: 13:858-0001070056.
37. Newman TB, Grady DG, Browner WS, Cummings SR, Hulley SB. Enhancing causal inference in observational studies (Chapter 9). In: Designing Clinical Research. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007, ISBN: 13:858-0001070056.
38. Magidson V, Khodjakov A. Circumventing photodamage in live-cell microscopy (Chapter 23). In: Leslie Wilson, Phong Tran (Eds.), Methods Cell Biol. 2013;114:545-560. http://dx.doi.org/10.1016/B978-0-12-407761-4.00023-3.
39. Aycicek A., Erel O. Total oxidant/antioxidant status in jaundiced newborns before and after phototherapy. J Pediatr (Rio J) 2007, 83(4):319-322.
40. Kurt A., Aygun A.D., Kurt A.N.C., Godekmerdan A., Akarsu S., Yilmaz E. Use of phototherapy for neonatal hyperbilirubinemia affects cytokine production and lymphocyte subsets. Neonatology 2009, 95(3):262-266.
41. Faddan N., El-Aziz N., El-Azeem H., Shreif T. Effect of phototherapy on blood levels of endothelin-1 and nitric oxide in hyberbilirubinemic newborn infants. E-J Neonatol Res 2014, 4(1):14-20.
42. Benders M.J., van Bel F., van de Bor M. The effect of phototherapy on cerebral blood flow velocity in preterm infants. Acta Paediatr 1998, 87(7):786-791.
43. Dani C., Bertini G., Martelli E., et al. Effects of phototherapy on cerebral haemodynamics in preterm infants: is fibre-optic different from conventional phototherapy?. Dev Med Child Neurol 2004, 46(2):114-118.
44. Pezzati M., Biagiotti R., Vangi V., Lombardi E., Wiechmann L., Rubaltelli F.F. Changes in mesenteric blood flow response to feeding: conventional versus fiber-optic phototherapy. Pediatrics 2000, 105(2):350-353.
45. Yao A.C., Martinussen M., Johansen O.J., Brubakk A.M. Phototherapy-associated changes in mesenteric blood flow response to feeding in term neonates. J Pediatr 1994, 124(2):309-312.
46. Soyer T., Ayva S., Aliefendioğlu D., et al. Effect of phototherapy on growth factor levels in neonatal rat skin. J Pediatr Surg 2011, 46(11):2128-2131.
47. De Sousa A.P.C., Paraguassú G.M., Silveira N.T.T., et al. Laser and LED phototherapies on angiogenesis. Lasers Med Sci 2013, 28(3):981-987.
48. Tozzi E., Tozzi-Ciancarelli M.G., Di Giulio A., et al. In vitro and in vivo effects of erythrocyte phototherapy on newborns. Biol Neonate 1989, 56(4):204-209.
49. Sisson T.R. Photodegradation of riboflavin in neonates. Fed Proc 1987, 46(5):1883-1885.
50. Silverman W.A. Human experimentation in perinatology. Clin Perinatol 1987, 14(2):403-416.
51. Antman E.M., Bennett J.S., Daugherty A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007, 115(12):1634-1642.
52. Effective Care of the Newborn Infant 1992, Oxford University Press, Oxford; New York. J.C. Sinclair, M.B. Bracken (Eds.).
53. Rothman K.J. A show of confidence. N Engl J Med 1978, 299(24):1362-1363.
54. Rothman K.J. Six persistent research misconceptions. J Gen Intern Med 2014, 29(7):1060-1064.
55. Lilford R.J., Thornton J.G., Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. Br Med J 1995, 311(7020):1621-1625.
56. Spiegelhalter D.J., Myles J.P., Jones D.R., Abrams K.R. An introduction to Bayesian methods in health technology assessment. Br Med J 1999, 319(7208):508-512.
57. Wijeysundera D.N., Austin P.C., Hux J.E., Beattie W.S., Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol 2009, 62(1):13-21. (e5).
58. McGrayne S. New Haven, The Theory That Would Not Die: How Bayes' Rule Cracked the Enigma Code, Hunted Down Russian Submarines, and Emerged Triumphant from Two Centuries of Controversy, Yale University Press; 2011. ISBN-10: 0300169698, ISBN-13: 978-0300169690.
59. Goodman S.N. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials 2005, 2(4):282-290. [discussion 301-304, 364-378].
60. Guyatt G., Wyer P., Ioannidis J. Summarizing the evidence: when to believe a subgroup analysis. Users[U+05F3] Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice 2008, McGraw-Hill Education, New York, NY. 2nd ed. G.H. Guyatt, D. Rennie, M.O. Meade, D.J. Cook (Eds.).
61. Sun X., Ioannidis J.A., Agoritsas T., Alba A.C., Guyatt G. How to use a subgroup analysis: users[U+05F3] guide to the medical literature. J Am Med Assoc 2014, 311(4):405-411.
62. Landry R.J., Scheidt P.C., Hammond R.W. Ambient light and phototherapy conditions of eight neonatal care units: a summary report. Pediatrics 1985, 75(2 Pt 2):434-436.
63. Seidman D.S., Moise J., Ergaz Z., et al. A prospective randomized controlled study of phototherapy using blue and blue-green light-emitting devices, and conventional halogen-quartz phototherapy. J Perinatol 2003, 23(2):123-127.
64. Ebbesen F., Madsen P., Støvring S., Hundborg H., Agati G. Therapeutic effect of turquoise versus blue light with equal irradiance in preterm infants with jaundice. Acta Paediatr 2007, 96(6):837-841.
65. Rubaltelli F.F. Blue light, green light, turquoise light: do we need to change our devices to treat our jaundiced preterm infants?. Acta Paediatr 2007, 96(6):792-793.
66. Lamola A.A., Bhutani V.K., Wong R.J., Stevenson D.K., McDonagh A.F. The effect of hematocrit on the efficacy of phototherapy for neonatal jaundice. Pediatr Res 2013, 74(1):54-60.
67. Maurer H.M., Shumway C.N., Draper D.A., Hossaini A.A. Controlled trial comparing agar, intermittent phototherapy, and continuous phototherapy for reducing neonatal hyperbilirubinemia. J Pediatr 1973, 82(1):73-76.
68. Vogl T.P., Hegyi T., Hiatt I.M., Polin R.A., Indyk L. Intermediate phototherapy in the treatment of jaundice in the premature infant. J Pediatr 1978, 92(4):627-630.
69. Lau S.P., Fung K.P. Serum bilirubin kinetics in intermittent phototherapy of physiological jaundice. Arch Dis Child 1984, 59(9):892-894.
70. Niknafs P., Mortazavi A.-A., Torabinejad M.H., Bahman-Bijari B., Niknafs N. Intermittent versus continuous phototherapy for reducing neonatal hyperbilirubinemia. Iran J Pediatr 2008, 18(3):251-256.
71. Vogl T.P., Cheskin H., Blumenfeld T.A., Speck W.T., Koenigsberger M.R. Effect of intermittent phototherapy on bilirubin dynamics in Gunn rats. Pediatr Res 1977, 11(10 Pt 1):1063-1068.
72. Vogl T.P., Cheskin H.S., Blumenfeld T.A., Sugai G.K. Bilirubin dynamics in the Gunn rat. Dose response of intermittent and continuous phototherapy. Biol Neonate 1980, 38(1-2):106-112.
73. Ballowitz L., Geutler G., Krochmann J., Pannitschka R., Roemer G., Roemer I. Phototherapy in Gunn rats. A study to assess the photobiologically most effective radiant energy and dose/response relationships. Biol Neonate 1977, 31(3-4):229-244.
74. Donneborg M.L., Knudsen K.B., Ebbesen F. Effect of infants[U+05F3] position on serum bilirubin level during conventional phototherapy. Acta Paediatr 2010, 99(8):1131-1134.
75. Mreihil K., McDonagh A.F., Nakstad B., Hansen T.W.R. Early isomerization of bilirubin in phototherapy of neonatal jaundice. Pediatr Res 2010, 67(6):656-659.
76. Vreman H.J., Cipkala D.A., Stevenson D.K. Characterization of porphyrin heme oxygenase inhibitors. Can J Physiol Pharmacol 1996, 74(3):278-285.
77. Wong R.J., Bhutani V.K., Vreman H.J., Stevenson D.K. Pharmacology review tin mesoporphyrin for the prevention of severe neonatal hyperbilirubinemia. Neoreviews 2007, 8(2):e77-e84.
78. Stevenson D.K., William A. Silverman lecture. J Perinatol 2014, 34(1):1-5.
79. Vreman H.J., Rodgers P.A., Gale R., Stevenson D.K. Carbon monoxide excretion as an index of bilirubin production in rhesus monkeys. J Med Primatol 1989, 18(6):449-460.
80. Vreman H.J., Rodgers P.A., Stevenson D.K. Zinc protoporphyrin administration for suppression of increased bilirubin production by iatrogenic hemolysis in rhesus neonates. J Pediatr 1990, 117(2 Pt 1):292-297.
81. Kappas A., Drummond G.S., Manola T., Petmezaki S., Valaes T. Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics 1988, 81(4):485-497.
82. Martinez J.C., Garcia H.O., Otheguy L.E., Drummond G.S., Kappas A. Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Pediatrics 1999, 103(1):1-5.
83. Kappas A., Drummond G.S., Valaes T. A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns. Pediatrics 2001, 108(1):25-30.